ABSTRACT
The aim of this study was to find an optimal analgesic dose of amitriptyline, and at the same time examine whether a therapeutic window existed for this analgesic effect. 85 patients with chronic, non-malignant pain were included in a double-blind treatment regime with four doses of amitriptyline (10, 25, 50 or 100 mg). A blood sample was taken at steady state. The results showed 25 mg amitriptyline to have a good analgesic and sleep regulatory effect. The four different doses of amitriptyline did not show any significant difference in efficacy. No therapeutic window was found, but one cannot exclude that it exists. Low-dose amitriptyline, as a non-addictive drug, is a good alternative in the treatment of chronic pain, independent of co-morbid depression.
Subject(s)
Amitriptyline/administration & dosage , Antidepressive Agents, Tricyclic/administration & dosage , Pain/drug therapy , Adult , Aged , Amitriptyline/blood , Analgesics/administration & dosage , Analgesics/blood , Antidepressive Agents, Tricyclic/blood , Chronic Disease , Double-Blind Method , Female , Humans , Male , Middle Aged , Pain MeasurementABSTRACT
BACKGROUND: We compared the efficacy of two neuroleptics with different receptor profiles (zuclopenthixol and haloperidol) in learning disabled patients with behavioural disturbance. METHOD: A double-blind crossover study (2 x 8 weeks; n = 34), interrupted by a two-week single-blind washout period, was employed. Assessments included the Schedule for Handicaps, Behaviour, and Skills (SHBS) and Clinical Global Impression (CGI). RESULTS: The SHBS score was significantly reduced for the zuclopenthixol cohort only. End-point analysis between the two drugs also showed an enhanced effect for zuclopenthixol over haloperidol. CGI scores did not reveal significant differences between the two drugs. CONCLUSION: Zuclopenthixol may be superior to haloperidol for the treatment of behavioural disturbances in mentally retarded subjects.
Subject(s)
Clopenthixol/therapeutic use , Haloperidol/therapeutic use , Intellectual Disability/drug therapy , Learning Disabilities/drug therapy , Social Behavior Disorders/drug therapy , Adult , Behavior Therapy , Clopenthixol/adverse effects , Combined Modality Therapy , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Haloperidol/adverse effects , Humans , Intellectual Disability/psychology , Learning Disabilities/psychology , Male , Middle Aged , Single-Blind Method , Social Behavior Disorders/psychology , Treatment OutcomeABSTRACT
A length difference of about 50 bp in the EcoRI fragment B of the rDNA from two different strains of Saccharomyces cerevisiae has been mapped in detail by sequencing of cloned fragments. This 2.4 kb EcoRI fragment contains the start of the 35S rRNA gene at one end and the 5S rRNA gene in the middle flanked by non-transcribed spacers, NTS1 and NTS2. The difference appeared as short deletions or insertions in five regularly spaced regions within the 1 kb NTS1, 3' to the 5S rRNA gene. The same regions of heterogeneities were displayed when all available sequence data of the NTS1 were compared. Four of the variable regions are located 160-170 bp apart, indicating that they might represent linker sequences between phased nucleosomes. Two variant clones, differing in the length of one subfragment of NTS1, were isolated for each strain. In both cases these represented the major variants among chromosomal NTS1 as revealed by sequencing of genomic fragments.
